Yulia Slavina

Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies

Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies
Bicara Therapeutics Inc. joins ACS CAN

Bicara Therapeutics Inc. participated in a Research Breakfast hosted by ACS CAN, underlining its alignment with advocates of evidence-based cancer policy.

The company reiterated its dedication to supporting initiatives that reduce the cancer burden and to developing meaningful therapies for patients. Bicara Therapeutics Inc. expressed gratitude for the opportunity to contribute alongside the advocacy group, indicating a continued partnership in the pursuit of improved patient outcomes.

Bicara recently announced Ficerafusp alfa as the first EGFR-directed antibody-TGF-beta trap for HPV-negative HNSCC. The company has also initiated the FORTIFI clinical trial to address unmet needs for HPV-negative HNSCC patients with poor prognosis. These efforts reflect Bicara’s focus on advancing new treatment options for cancer patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.